C1orf91 Inhibitors
C1orf91 Inhibitors encompass a spectrum of chemical compounds that indirectly constrain the functional activity of C1orf91 by targeting various signaling pathways. LY 294002 and Wortmannin, as PI3K inhibitors, undermine the PI3K/Akt pathway, a cascade that is instrumental in cell survival and growth, indirectly leading to the diminishment of C1orf91 activity if it is associated with this pathway. Similarly, the inhibition of MEK by PD 98059 and U0126 results in the suppression of the ERK pathway, which correlates with a decrease in C1orf91 functionality. The mTOR signaling axis, another regulator of cell growth, is targeted by Rapamycin, consequently diminishing the activity of C1orf91 if it is under the purview of mTOR-mediated control. Moreover, SB 203580's targeting of p38 MAPK and SP600125's inhibition of JNK signaling further illustrate how the blockage of key MAPK pathways can indirectly result in the functional inhibition of C1orf91.
The capacity of C1orf91 to influence cellular processes is also attenuated by compounds such as Y-27632, which inhibits the Rho-associated protein kinase (ROCK) pathway, pivotal in actin cytoskeleton organization and potentially in regulating C1orf91's activity. Gefitinib and Imatinib, by selectively inhibiting tyrosine kinases like EGFR, BCR-ABL, c-KIT, and PDGFR, attenuate downstream signaling that may incorporate C1orf91, thus indirectly diminishing its functional role. Bortezomib's action in inhibiting proteasomal degradation can affect the turnover of signaling proteins that modulate C1orf91's activity. Triciribine specifically targets AKT, an upstream regulator in many signaling pathways, including those that might control C1orf91 activity, resulting in a functional decrease of this protein. Collectively, these inhibitors act on distinct but interrelated pathways that converge on the functional inhibition of C1orf91 without affecting its expression levels, reflecting a targeted approach to diminish its activity through upstream regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that leads to a decrease in PI3K/Akt signaling. Given that C1orf91 is involved in pathways regulated by PI3K/Akt, inhibition of this pathway by LY 294002 will diminish the functional activity of C1orf91. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK, which diminishes the MAPK signaling pathway. By inhibiting p38 MAPK, SB 203580 reduces the downstream signaling events in which C1orf91 is a participant, thereby diminishing its functional role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific MEK inhibitor that prevents the activation of ERK1/2. As C1orf91 operates downstream of the MEK/ERK pathway, PD 98059's inhibition of MEK indirectly leads to diminished activity of C1orf91. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent and irreversible inhibitor of PI3K which dampens the PI3K/Akt pathway. By inhibiting this pathway, Wortmannin indirectly reduces the activity of C1orf91, which is implicated in this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that, by inhibiting the mTORC1 complex, leads to diminished protein synthesis and cell growth signaling. C1orf91, being associated with growth-regulated pathways, is functionally diminished by rapamycin. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2 which prevents the activation of the downstream ERK pathway. C1orf91, functioning downstream of the ERK pathway, is indirectly inhibited by U0126. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which interferes with the JNK signaling pathway. This diminishes the functional activity of C1orf91 if it is regulated by JNK signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of the Rho-associated protein kinase (ROCK), leading to a decrease in actin cytoskeleton organization. C1orf91's functional activity is indirectly diminished if it is involved in pathways regulated by ROCK. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, gefitinib diminishes downstream signaling that can involve C1orf91, resulting in its functional inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that impedes the degradation of protein regulators of cell cycle and survival. The inhibition of this pathway indirectly leads to the functional diminishment of C1orf91 if it is regulated by proteasomal degradation. | ||||||